相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl et al.
BLOOD ADVANCES (2021)
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs
Lucia Masarova et al.
BLOOD ADVANCES (2021)
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
Yu-Wen Wang et al.
ANNALS OF HEMATOLOGY (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Venetoclax is safe and efficacious in relapsed/refractory AML
Chezi Ganzel et al.
LEUKEMIA & LYMPHOMA (2020)
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
Erika Morsia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia
Karamjeet S. Sandhu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D. DiNardo et al.
LANCET HAEMATOLOGY (2020)
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Catherine J. Lee et al.
BONE MARROW TRANSPLANTATION (2019)
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study
Ron Ram et al.
ANNALS OF HEMATOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
T. Schroeder et al.
LEUKEMIA (2013)